Figure 2From: Bevacizumab treatment for neovascular age-related macular degeneration in the setting of a clinic: “real life” long-term outcomeThe mean change (±SEM) in central point thickness (CPT) and central subfield thickness (CST) measurements along the follow up period. BEV #3 = third bevacizumab injection; OCT = optical coherence tomography; *p < 0.05 vs. initial; **p < 0.05 vs. 2 years.Back to article page